| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Net loss attributable to qualigen therapeutics, inc | -2,905,615 | -1,687,003 | -2,646,172 | |
| Total net loss per common share, basic | -4.68 | -1 | -1.82 | |
| Total net loss per common share, diluted | -4.68 | -1 | -1.82 | |
| Weighted-average number of shares outstanding, basic | 620,694 | 1,683,881 | 1,456,714 | |
| Weighted-average number of shares outstanding, diluted | 620,694 | 1,683,881 | 1,456,714 | |
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)